Priority Research Papers:
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
Metrics: PDF 211 views | Full Text 415 views | ?
Thomas B. Davis1, Mingli Yang1, Heiman Wang1, Changgong Lee2, Timothy J. Yeatman1,3,4 and W. Jack Pledger1,3
1 Department of Surgery, University of Utah, Salt Lake City, UT 84132, USA
2 Gibbs Cancer Center & Research Institute, Spartanburg, SC 29303, USA
3 Cell Response and Regulation Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA
4 Oncology Clinical Program, Intermountain Healthcare, Murray, UT 84107, USA
|W. Jack Pledger,||email:||email@example.com|
|Timothy J. Yeatman,||email:||firstname.lastname@example.org|
Keywords: colorectal cancer; PTPRS; ERK; SRC; adaptive resistance
Received: September 06, 2019 Accepted: November 07, 2019 Published: November 26, 2019
PTPRS is the most commonly mutated receptor tyrosine phosphatase in colorectal cancer (CRC). PTPRS has been shown to directly affect ERK and regulate its activation and nuclear localization. Here we identify that PTPRS may play a significant role in developing adaptive resistance to MEK/ERK inhibitors (MEKi/ERKi) through SRC activation. Moreover, we demonstrate a new clinical approach to averting adaptive resistance through the use of the SRC inhibitor, dasatinib. Our data suggest the potential for dasatinib to enhance the efficacy of MEKi and ERKi by preventing adaptive resistance pathways operating through SRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.